Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia

Journal of Psychopharmacology

Volumn 28, Issue 4, 2014, Pages 349-356

  Burghardt, K J ^a   Grove, T B ^a   Ellingrod, V L ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antipsychotic drugs; endothelial cells; endothelial function; inflammation; metabolic syndrome; nitric oxide synthetase; peripheral artery tonometry; pharmacogenetics; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ILOPERIDONE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT; NITRIC OXIDE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENOS GENE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; TONOMETRY; DISEASE COURSE; GENETICS; MANOMETRY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MANOMETRY; METABOLIC SYNDROME X; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHARMACOGENETICS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84896799316     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113516200     Document Type: Article

References (50)

1. Agema WR, Monraats PS, Zwinderman AH, et al. Current PTCA practice and clinical outcomes in The Netherlands: The real world in the pre-drug-eluting stent era. Eur Heart J. 2004 ; 25: 1163-1170
2. Alian Z, Hashemipour M, Dehkordi EH, et al. The effects of folic acid on markers of endothelial function in patients with Type 1 diabetes mellitus. Medicinski Arhiv. 2012 ; 66: 12-15
3. Andreasen NC, Pressler M, Nopoulos P, et al. Antipsychotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010 ; 67: 255-262
4. Antonopoulos AS, Margaritis M, Lee R, et al. Statins as anti-inflammatory agents in atherogenesis: Molecular mechanisms and lessons from the recent clinical trials. Curr Pharmaceut Design. 2012 ; 18: 1519-1530
5. Balakumar P, Kathuria S, Taneja G, et al. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?. J Molec Cell Cardiol. 2012 ; 52: 83-92
6. Bhanoori M. Endothelial nitric oxide synthase (eNOS) variants in cardiovascular disease: Pharmacogenomic implications. Indian J Med Res. 2011 ; 133: 464-466
7. Boger RH, Bode-Boger SM, Thiele W, et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997 ; 95: 2068-2074
8. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thrombo Vasc Biol. 2003 ; 23: 168-175
9. Bonetti PO, Pumper GM, Higano ST, et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004 ; 44: 2137-2141
10. Brenol CV, Chies JA, Brenol JC, et al. Role of endothelial nitric oxide synthase (eNOS) polymorphisms in cardiovascular disease and rheumatoid arthritis. Clin Exp Rheumatol. 2010 ; 28: 584-585
11. Celermajer DS, Sorensen KE, Spiegelhalter DJ, et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994 ; 24: 471-476
12. Da Costa Escobar Piccoli J, Manfredini V, Hamester FI, et al. Interaction between endothelial nitric oxide synthase gene polymorphisms (-786T>C, 894G>T and Intron 4 a/b) and cardiovascular risk factors in acute coronary syndromes. Arch Med Res. 2012 ; 43: 205-211
13. Diodati JG, Dakak N, Gilligan DM, et al. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation. 1998 ; 98: 17-24
14. Egashira K, Inou T, Hirooka Y, et al. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation. 1993 ; 88: 77-81
15. Ellingrod VL, Taylor SF, Brook RD, et al. Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). Schizophr Res. 2011 ; 130: 20-26
16. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diab Care. 2005 ; 28: 2745-2749
17. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med. 2006 ; 119: 812-819
18. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007 ; 49: 403-414
19. Grassi D, Desideri G, Ferri L, et al. Oxidative stress and endothelial dysfunction: Say NO to cigarette smoking!. Curr Pharmaceut Design. 2010 ; 16: 2539-2550
20. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005 ; 112: 2735-2752
21. Guo H, Chi J, Xing Y, et al. Influence of folic acid on plasma homocysteine levels and arterial endothelial function in patients with unstable angina. Indian J Med Res. 2009 ; 129: 279-284
22. Hamburg NM, Palmisano J, Larson MG, et al. Relation of brachial and digital measures of vascular function in the community: The Framingham heart study. Hypertension. 2011 ; 57: 390-396
23. Hein TW, Singh U, Vasquez-Vivar J, et al. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 2009 ; 206: 61-68
24. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005 ; 150: 1115-1121
25. Imamura A, Takahashi R, Murakami R, et al. The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: The significance of plasma adiponectin levels. Eur J Endocrinol. 2008 ; 158: 189-195
26. Ingelsson E, Sullivan LM, Murabito JM, et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes. 2007 ; 56: 1718-1726
27. Israel AK, Seeck A, Boettger MK, et al. Peripheral endothelial dysfunction in patients suffering from acute schizophrenia: A potential marker for cardiovascular morbidity?. Schizophr Res. 2011 ; 128: 44-50
28. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: Insights from therapeutic interventions. J Am Coll Cardiol. 2005 ; 46: 1978-1985
29. Kusche-Vihrog K, Urbanova K, Blanque A, et al. C-reactive protein makes human endothelium stiff and tight. Hypertension. 2011 ; 57: 231-237
30. Lahiri DK, Nurnberger JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Ac Res. 1991 ; 19: 5444
31. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Op Psychiatry. 2012 ; 25: 83-88
32. Lee SC, Pu YB, Thomas GN, et al. Tumor necrosis factor alpha gene G-308A polymorphism in the metabolic syndrome. Metab Clin Exper. 2000 ; 49: 1021-1024
33. Leonard BE, Schwarz M, Myint AM. The metabolic syndrome in schizophrenia: Is inflammation a contributing cause?. J Psychopharmacol. 2012 ; 26: 33-41
34. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005 ; 80: 19-32
35. Marsh S, King CR, Garsa AA, et al. Pyrosequencing of clinically relevant polymorphisms. Meth Molec Biol. 2005 ; 311: 97-114
36. Metzger IF, Sertorio JT, Tanus-Santos JE. Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radical Biol Med. 2007 ; 43: 987-992
37. Metzger IF, Souza-Costa DC, Marroni AS, et al. Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genom. 2005 ; 15: 565-570
38. Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Schizophr Res. 2005 ; 80: 9-18
39. Napoli C, Ignarro LJ. Polymorphisms in endothelial nitric oxide synthase and carotid artery atherosclerosis. J Clin Pathol. 2007 ; 60: 341-344
40. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), final report. Circulation. 2002 ; 106: 3143-3421
41. Orrell A, Doherty P, Miles J, et al. Development and validation of a very brief questionnaire measure of physical activity in adults with coronary heart disease. Eur J Cardiovasc Prevention Rehab. 2007 ; 14 (5). 615-623
42. Pons D, Monraats PS, Zwinderman AH, et al. Metabolic background determines the importance of NOS3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndrome. Dis Markers. 2009 ; 26: 75-83
43. Prossin AR, Zalcman SS, Evans SJ, et al. A pilot study investigating tumor necrosis factor-alpha as a potential intervening variable of atypical antipsychotic-associated metabolic syndrome in bipolar disorder. Therapeut Drug Monitor. 2013 ; 35: 194-202
44. Puranik R, Celermajer DS. Smoking and endothelial function. Prog Cardiovasc Dis. 2003 ; 45: 443-458
45. Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Investigat. 1995 ; 95: 1747-1755
46. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010 ; 31: 1142-1148
47. Sandrim VC, De Syllos RW, Lisboa HR, et al. Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with Type 2 diabetes mellitus. Atherosclerosis. 2006 ; 189: 241-246
48. Sena CM, Pereira AM, Seica R. Endothelial dysfunction: A major mediator of diabetic vascular disease. Biochim Biophys Acta. 2013 ; 1832: 2216-2231
49. Tanus-Santos JE, Desai M, Flockhart DA. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics. 2001 ; 11 (8). 719-725
50. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002 ; 106: 1439-1441